Fruquintinib dosage and usage

Fruquintinib is an oral multi-target small molecule kinase inhibitor mainly used to treat advanced gastric cancer or colorectal cancer. When using fruquintinib, patients need to strictly follow the doctor's recommendations and use the medication rationally according to the prescribed dosage and usage to ensure the effectiveness of the treatment and reduce the occurrence of adverse reactions.

1. Basic principles of dosage and usage: The dosage and usage of fruquintinib need to be determined according to the patient’s specific illness, physical condition and the doctor’s recommendations. Generally speaking, the recommended dosage is oral administration, 1 times a day, 5mg each time. The treatment cycle is 4 weeks, and then the drug is stopped for 1 weeks, forming a complete treatment cycle. Patients should take the medication on time and not change the dosage or stop the medication at will to ensure the stability and therapeutic effect of the medication.

2. Pre-medication examination and evaluation: Before starting fruquintinib treatment, doctors usually conduct a comprehensive physical examination and medical history to evaluate the patient's overall health. Particularly for older patients and those with other medical conditions, more careful evaluation may be needed. This helps determine the dosage and usage that is best for the patient and if there are any contraindications or areas that require special attention.

3. Dose time and meals: Fruquintinib is usually taken on an empty stomach, that is, within 30 minutes to 1 hour before meals, in order to improve its absorption effect. Patients should avoid taking it immediately after a meal to reduce interactions with food. If a patient experiences gastrointestinal reactions while taking the medication, the doctor may recommend eating before or after taking the medication to relieve discomfort.

4. Precautions when taking medication: During the medication period, patients should follow the doctor's advice and undergo relevant examinations regularly. If a dose is missed, the patient should not replenish the dose but should take the normal dose at the next prescribed time. At the same time, patients should avoid using it at the same time with other drugs that may affect drug absorption or increase side effects, such as nonsteroidal anti-inflammatory drugs, antibiotics, etc.

5. Monitoring and treatment of side effects: During the medication period, patients need to pay close attention to their own reactions and symptoms. Fruquintinib may cause a series of side effects, including but not limited to fatigue, loss of appetite, hypertension, hand-foot syndrome, gastrointestinal reactions, etc. If the patient feels unwell, he or she should report it to the doctor in time for appropriate monitoring and treatment. Doctors may adjust medication regimens, use supportive care, or suspend medications to protect the patient's overall health.

6. Regular follow-up and adjustment of treatment plan: Patients need regular follow-up during the medication period to ensure the stability of the efficacy and to detect potential problems in a timely manner. Doctors may adjust the medication plan according to the patient's specific conditions, including adjusting the dose or suspending treatment, to maximize the patient's safety and efficacy.

7. Precautions when ending treatment: When a patient ends fruquintinib treatment, the doctor will evaluate whether it is necessary to gradually reduce the dose or directly discontinue the drug based on the condition. Patients should not stop taking the medicine on their own without the guidance of a doctor to avoid affecting the therapeutic effect. In addition, the doctor may recommend a period of follow-up to monitor the progression of the disease and ensure the patient's recovery status.

In general, the dosage and usage of fruquintinib requires patients to closely follow the doctor's recommendations and cooperate with regular examinations and follow-up. This can ensure the safety and effectiveness of treatment to the greatest extent and improve the patient's quality of life. Close communication between doctor and patient will play a vital role throughout the treatment process.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.